<DOC>
	<DOCNO>NCT03068936</DOCNO>
	<brief_summary>Nasopharyngeal carcinoma high incidence southern China , especially Guangdong Province . In world , standardized morbidity reach 30/10 million men woman , 13/10 million . At present , incidence nasopharyngeal carcinoma China account 80 % world . The cancer-related death eighth , serious threat people 's health life . A recent multi-center phase II study stage II nasopharyngeal carcinoma show : compare Intensity Modulation Radiotherapy ( IMRT ) plus cisplatin , 3 year local control rate , regional control rate , distant metastasis-free survival rate disease-specific survival rate IMRT similar , side effect radiotherapy alone group lower . Based result phase II clinical study , investigator design phase III clinical study , aim compare efficacy toxicity two treatment program . And finally provide sufficient evidence treatment stage II nasopharyngeal carcinoma .</brief_summary>
	<brief_title>IMRT Plus Cisplatin Versus IMRT Patients With Stage 2 Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>The sex subject limit , age 18 70 year old ; Histologically prove nasopharyngeal squamous cell carcinoma , World Health Organization ( WHO ) IIIII type ; Union Internationale Contre le Cancer ( UICC ) stage 9 clinical stage II patients； Karnofsky score ≥ 80 point ; No evidence distant metastasis ; Having nasopharyngeal MRI treatment , measure size tumor order analyze effect . The subject previously suffer malignancy ( except nonmelanotic skin cancer cervical carcinoma situ ) ; Previously receive immunotherapy ; Previously receive chemotherapy ; Previously receive radiation therapy ; Patients previously undergone surgical treatment head neck tumor ( exclude cervical lymphadenectomy ) ; Evidence distant metastasis malignancy time .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>Intensity modulate radiotherapy</keyword>
	<keyword>Cisplatin</keyword>
</DOC>